Showing 6261-6270 of 6664 results for "".
- Modernizing Medicine Announces Inaugural EMA Nation Users Conferencehttps://practicaldermatology.com/news/20140903-modernizing_medicine_announces_inaugural_ema_nation_users_conference/2459133/Modernizing Medicine, Inc., creator of the Electronic Medical Assistant (EMA), announces its inaugural EMA Nation Users Conference. The conference will provide a venue for users of this specialty-specific electronic health record (EHR) system to network and learn how to use EMA's expanding capabilit
- Solace International Issues Recall of Dermatend Original and Dermatend Ultrahttps://practicaldermatology.com/news/20140902-solace_international_issues_recall_of_dermatend_original_and_dermatend_ultra/2459134/Solace International, Inc. is voluntarily recalling all lots of Dermatend Original and Dermatend Ultra in all sizes and dosage form to the distributor/wholesaler level. A mole should be removed under the supervision of a dermatologist. Dermatend is not FDA approved, thus has not
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce
- Trevi Therapeutics Announces the Issuance of Two Patents for Oral Sustained Release Formulation of Nalbuphine ERhttps://practicaldermatology.com/news/20140815-trevi_therapeutics_announces_the_issuance_of_two_patents_for_oral_sustained_release_formulation_of_nalbuphine_er/2459144/Trevi Therapeutics, Inc. received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175. The Company believes that both of these patents will be Orange Book-li
- Syneron Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosishttps://practicaldermatology.com/news/20140815-syneron_introduces_new_fda-cleared_5mm_spot_size_for_treatment_of_onychomycosis/2459145/Syneron Medical Ltd. launched a new handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series. The introduction of this new FDA-cleared handp
- Justin Chickles Joins myoscience as Vice President of Commercial Development & Johanna Beckmen Becomes General Manager of Aestheticshttps://practicaldermatology.com/news/20140812-justin_chickles_joins_myoscience_as_vice_president_of_commercial_development__johanna_beckmen_becomes_general_manager_of_aesthetics/2459148/Justin Chickles is now Vice President of Commercial Development and Johanna Beckmen is now promoted to General Manager of Aesthetics of Myoscience, Inc. Chickles Said, "Myoscience's ioveradegrees treatment is poised to become a transformative therapy for patients living with pain.The pas
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bu
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101.
- Cynosure Appoints Timothy W. Baker as Presidenthttps://practicaldermatology.com/news/20140730-cynosure_appoints_timothy_w_baker_as_president/2459154/The Board of Directors of Cynosure, Inc., which develops and markets laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to Presi
- TSLMS Presents the 10th Annual SCALE Meetinghttps://practicaldermatology.com/news/20140728-tslms_presents_the_10th_annual_scale_meeting/2459157/The Omni Hotel in Nashville, TN will host the 10th annual SCALE meeting March 6-8, 2015. Sponsored by the Tennessee Society for Laser Medicine & Surgery, the Symposium for Cosmetic Advances and Laser Education is now accepting applications for exhibitors and accepting registrations.